• breast cancer - triple negative 1
• breast cancer - triple negative metastatic
• mBC - Triple negative (TNBC) - (neo)adjuvant (NA) 1
• mBC - Triple negative (TNBC) - 1st Line (L1) 2
• la/mBC - TNBC - L1 - all population 8
• la/mBC - TNBC - L1 - PDL1 positive 5
• mBC-Triple negative (TNBC) - 2nd Line (L2) 3
• la/mBC - TNBC - L2 - all population 6
• la/mBC - TNBC - L2 - PDL1 positive 7
• es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) 4
• es-BC - TNBC - NA - all population 7
• es-BC - TNBC - NA - PDL1 positive 1
• es-BC - Triple negatif (TNBC) - 1st line (L1)

 

• chemotherapy
• non platinum-based chemotherapy
• anthracyclines
• nucleoside analogues (pyrimidine/purine)
• gemcitabine
• taxanes
• paclitaxel
• nab-paclitaxel
• pegylated liposomal doxorubicin and cyclophosphamide
• platinum-based chemotherapy
• platinum derivate
• carboplatin
• cyclophosphamide
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• durvalumab based treatment
• durvalumab alone
• mTOR inhibitors
• everolimus
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab

• versus all
• vs chemotherapy
• vs pegylated liposomal doxorubicin and cyclophosphamide
• vs platinum-based chemotherapy
• vs platinum derivate
• vs carboplatin
• vs platinum association
• vs paclitaxel plus carboplatin
• vs Standard of Care (SoC)
• vs placebo plus paclitaxel
• vs poly ADP-ribose polymerase (PARP) inhibitor
• vs olaparib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)